Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? ; volume:81 ; number:16 ; day:27 ; month:10 ; year:2021 ; pages:1859-1879 ; date:11.2021
Drugs ; 81, Heft 16 (27.10.2021), 1859-1879, 11.2021
- Creator
-
Mysler, Eduardo
Azevedo, Valderilio Feijó
Danese, Silvio
Alvarez, Daniel
Iikuni, Noriko
Ingram, Beverly
Mueller, Markus
Peyrin-Biroulet, Laurent
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-021-01610-1
- URN
-
urn:nbn:de:101:1-2022012208354097457811
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mysler, Eduardo
- Azevedo, Valderilio Feijó
- Danese, Silvio
- Alvarez, Daniel
- Iikuni, Noriko
- Ingram, Beverly
- Mueller, Markus
- Peyrin-Biroulet, Laurent
- SpringerLink (Online service)
Other Objects (12)
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
Current status and considerations on biosimilar in China
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
Current status and considerations on biosimilar in China
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar
Correction to: AVT04: An Ustekinumab Biosimilar
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies
Current status and considerations on biosimilar in China
AVT02: An Adalimumab Biosimilar
SB8: A Bevacizumab Biosimilar
AVT04: An Ustekinumab Biosimilar
MYL-1402O: A Bevacizumab Biosimilar
Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
Mitigating the Nocebo Effect in Biosimilar Use and Switching: A Systematic Review
Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the First Biosimilar Natalizumab
PF-06438179/GP1111: An Infliximab Biosimilar